Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report) – Equities researchers at HC Wainwright issued their FY2027 EPS estimates for shares of Immix Biopharma in a research note issued on Monday, August 10th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.20) per share for the year. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.69) per share.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01).
Get Our Latest Stock Analysis on IMMX
Immix Biopharma Stock Performance
IMMX opened at $10.13 on Tuesday. Immix Biopharma has a one year low of $1.94 and a one year high of $12.14. The company has a market cap of $551.17 million, a P/E ratio of -11.51 and a beta of 0.11. The business’s 50-day simple moving average is $9.40 and its 200-day simple moving average is $8.89.
Institutional Trading of Immix Biopharma
Institutional investors and hedge funds have recently modified their holdings of the business. LGT Fund Management Co Ltd. boosted its stake in shares of Immix Biopharma by 233.3% during the first quarter. LGT Fund Management Co Ltd. now owns 416,594 shares of the company’s stock valued at $3,795,000 after acquiring an additional 291,594 shares during the last quarter. Eventide Asset Management LLC acquired a new stake in Immix Biopharma during the fourth quarter worth approximately $13,331,000. Janus Henderson Group PLC raised its holdings in Immix Biopharma by 22.5% in the 1st quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock valued at $43,698,000 after acquiring an additional 880,434 shares during the last quarter. Blue Owl Capital Holdings LP acquired a new stake in shares of Immix Biopharma during the fourth quarter worth $5,158,000. Finally, Everhart Financial Group Inc. acquired a new position in Immix Biopharma in the second quarter valued at $103,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.
About Immix Biopharma
Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.
The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.
Featured Stories
- Five stocks we like better than Immix Biopharma
- 3 Overlooked Stocks Analysts Still Like as AI Trades Get Crowded
- China’s Athleisure Boom Is Not Lifting Every Brand Equally
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
-company-of-china-ltd-logo-1200x675.jpg){kind=logo}
